Recent Quotes

My Watchlist

Indicators

Xbiotech Inc (NQ: XBIT )

7.300 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	7.300
Bid (Size)	6.630 (3)
Ask (Size)	9.000 (5)
Prev. Close	7.300
Today's Range	7.300 - 7.300
52wk Range	3.510 - 9.960
Shares Outstanding	30,436,964
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XBIT Stock Earnings: XBiotech Reported Results for Q2 2024

August 12, 2024

XBiotech just reported results for the second quarter of 2024.

Via InvestorPlace

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

June 18, 2024

XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin...

Via Benzinga

Performance

YTD	+68.20%	+68.20%
1 Month	-5.19%	-5.19%
3 Month	+11.62%	+11.62%
6 Month	-14.72%	-14.72%
1 Year	+85.75%	+85.75%

More News

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

June 18, 2024

From XBiotech Inc.

Via GlobeNewswire

XBIT Stock Earnings: XBiotech Reported Results for Q1 2024

May 13, 2024

Via InvestorPlace

XBIT Stock Earnings: XBiotech Reported Results for Q4 2023

March 18, 2024

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday

October 20, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session

January 22, 2024

Via Benzinga

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

January 04, 2024

From XBiotech Inc.

Via GlobeNewswire

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

November 14, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

September 26, 2023

From XBiotech Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session

September 05, 2023

Via Benzinga

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

August 30, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

August 08, 2023

From XBiotech Inc.

Via GlobeNewswire

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

May 22, 2023

From XBiotech Inc.

Via GlobeNewswire

Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

May 17, 2023

Via Benzinga

Dow Jumps Over 100 Points; US Housing Starts Rise In April

May 17, 2023

Via Benzinga

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

May 17, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

April 17, 2023

From XBiotech Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday

November 28, 2022

Via Benzinga

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

October 13, 2022

From XBiotech Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday

August 22, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday

September 22, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday

September 20, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday

September 19, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday

August 31, 2022

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.